Immune Responses Following Locoregional Treatment for Hepatocellular Carcinoma: Possible Roles of Adjuvant Immunotherapy
Open Access
- 2 September 2021
- journal article
- review article
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (9) , 1387
Abstract
Hepatocellular carcinoma (HCC) is a common cause of cancer-related deaths worldwide. Unlike other types of cancer, HCC can be treated with locoregional treatments (LRTs) such as radiofrequency ablation (RFA) or transarterial chemoembolization (TACE). However, recurrences following LRTs are common, and strategies to improve long-term outcomes need to be developed. The exhaustion of anti-tumor immunity in HCC has been well established in many reports and the immunomodulatory effects of LRTs (enhancement of tumor antigen-specific T cell responses after RFA, reduction of effector regulatory T cells after TACE) have also been reported in several previous studies. However, a comprehensive review of previous studies and the possible roles of immunotherapy following LRTs in HCC are not known. In this review, we discuss the immunological evidence of current clinical trials using LRTs and combined immunotherapies, and the possible role of this strategy.Keywords
Funding Information
- Research Fund of Seoul St. Mary’s Hospital, The Catholic University of Korea (NA)
- Daewoong Foundation (DY20201P)
This publication has 104 references indexed in Scilit:
- Peptidases released by necrotic cells control CD8+ T cell cross-primingJournal of Clinical Investigation, 2013
- Anticancer activity of cardiac glycosidesOncoImmunology, 2012
- Insufficient Radiofrequency Ablation Promotes Angiogenesis of Residual Hepatocellular Carcinoma via HIF-1α/VEGFAPLOS ONE, 2012
- Upregulation of Circulating PD-L1/PD-1 Is Associated with Poor Post-Cryoablation Prognosis in Patients with HBV-Related Hepatocellular CarcinomaPLOS ONE, 2011
- Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1Journal of Experimental Medicine, 2009
- Radiofrequency Ablation Induces Antigen-presenting Cell Infiltration and Amplification of Weak Tumor-induced ImmunityRadiology, 2009
- Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies #Hepatology, 2009
- Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunityBritish Journal of Cancer, 2006
- Increase of CD4+CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinomaJournal of Hepatology, 2006
- Activation of dendritic cells by local ablation of hepatocellular carcinomaJournal of Hepatology, 2005